Wednesday, 25 Apr 2018

You are here

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The current report used the Behavioral Risk Factor Surveillance System (BRFSS) telephone survey of adults ≥18 years in the United States to assess the age-standardized prevalences of arthritis, arthritis health-related characteristics, and means of arthritis management.

The prevalence of arthritis was 23.0% (range: 17.2%–33.6%); with significant variability by county (range: 11.2%–42.7%).

Arthritis prevalence ranged from a low of 17.2% in Hawaii to a high of 33.6% in West Virginia. At the county level, counties in Appalachia and along the lower Mississippi River tended to have higher predicted prevalences of arthritis. The majority of counties in Alabama, Arkansas, Kentucky, Michigan, Missouri, Tennessee, and West Virginia were in the highest quartile (31.2%–42.7%).

Prevalence* of arthritis among adults aged ≥18 years, by county — Behavioral Risk Factor Surveillance System, 2015

Map of the United States indicates prevalence of arthritis among adults aged 18 years and older, by county. The data source is the 2015 Behavioral Risk Factor Surveillance System.

  • The prevalence of arthritis among adults with obesity was 30.9% (range: 24.6% in Texas to 41.2% in West Virginia).
  • The prevalence of arthritis among adults with coronary heart disease was 44.5% (range: 25.6% in DC to 72.6% in Iowa).
  • The prevalence of arthritis among adults with diabetes was 37.3% (range: 27.1% in California to 53.7% in Maine).

Only 13 states have an arthritis management module. Participation in a self-management education course for arthritis was 14.5% (range: 9–19%). Far more were insstructed by a a health care provider to engage in physical activity or exercise (58.5%; range: 52.3%–61.9%), and 44.5% (range: 35.1%–53.2%). were told to lose weight (if overweight or obese).

States with the highest prevalence of arthritis had the highest percentages of arthritis-related health consequences, such as characteristic activity limitations, severe joint pain, and arthritis-attributable social participation restriction, and the lowest percentage of leisure-time walking.

The prevalence of arthritis its management varied across the United States and presents variable challenges in health care delivery at the state and county level. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.